Comparative activity of doripenem, meropenem and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study;Actividad comparativa de doripenem, meropenem e imipenem en aislados recientes obtenidos durante el estudio de vigilancia epidemiológica COMPACT-España

Revista Espanola de Quimioterapia

Volumn 23, Issue 3, 2010, Pages 144-152

  Gimeno, C ^a   Canton R ^b   Garcia A ^c   Gobernado, M ^d  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Carbapenems; Doripenem; Pseudomonas aeruginosa; Surveillance study

Indexed keywords

DORIPENEM; IMIPENEM; MEROPENEM;

ABDOMINAL INFECTION; ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG INDICATION; ENTEROBACTERIACEAE; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NOSOCOMIAL PNEUMONIA; PNEUMONIA; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; SPAIN; URINARY TRACT INFECTION;

ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CARBAPENEMS; ENTEROBACTERIACEAE INFECTIONS; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS INFECTIONS; SPAIN; THIENAMYCINS;

EID: 78651352483     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Walsh TR. Clinically significant carbapenemases:un update. Curr Opin Infect Dis 2008; 21: 367-71.
2. Slama TG. Gram-negative antibiotic resistance: there is a play to pay?. Crit Care 2008; 12 (Suppl 4): S4.
3. Mendes RE, Rhomberg PR, Bell JM, Turnidge JD, Sader HS. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. Diag Microbiol Infect Dis 2009; 63: 415-25.
4. Keam SJ. Doripenem: A review of its use in the treatment of bacterial infections. Drugs 2008; 68: 2021-57.
5. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator associated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36: 1089-96.
6. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Therapeutics 2008: 30: 868-83.
7. Wagenlehner ME, Wagenlehner C, Redman R, Weidner W, Naber KG. Urinary bactericidal activity of doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. Antimicrob Agents Chemother 2009; 53: 1567-73.
8. Livermore DM. Doripenem: antimicrobial profile and clinical potential. Diag Microbiol Infect Dis 2009; 455-8.
9. Paterson DL, DePestel DD. Doripenem. Clin Infect Dis 2009;49:291-8.
10. Davies TA, Shang W, Bush K, Flamm RK. Affinity of doripenem and comparators to penicillin binding protens in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008; 52: 1510-12.
11. Castanheira M, Jones R, Livermore D. Antimicrobial activities of doripenem and other carbapenem against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diag Microbiol Infecti Dis 2009; 63: 426-33.
12. Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y. Potency of carbapenems for the prevention of carbapenem-resistant m utants of Pseudomonas aeruginosa: the high potency of new carbapenem doripenem. J Antibiot (Tokyo) 2006; 59: 220-8.
13. Tanimoto KH, Tomita H, Fujimoto S, Okuzumi K, Ike Y. Fluorquinolones enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibit mutation formation. Antimicrob Agents Chemother 2008; 52: 3795-3800.
14. Nagasawa Z, Kusaba K, Aoki Y. Susceptibility of clinical isolates of Pseudomonas aeruginosa in the Northern Kyushu district of Japan to carbapenem antibiotics, determined by an integrated concentration method: evaluation of the method based on Monte Carlo simulation. J Infect Chemother 2008; 14:238-43.
15. Mutters R, Morgan M, Nordmann P, Quintana A, Laeuffer JM, Cooper D, et al. Comparative susceptibility of European Gramnegative rods to doripenem, imipenem and meropenem. 19th European Congress of Clinical Microbiology and Infectious Diseases. Helsinki, Finland, 16-19 May 2009. Abstract: P1034.
16. Morrissey I, Rossolini G, Bouza E, Korten V, Kozlov R, Quintana A, et al. In vitro activity of doripenem (DOR), imipenem (IMP) and meropenem (MEM) against contemporary gram-negative pathogens circulating in nine countries. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, September 12-15, 2009. Abstract: 178.
17. Yee YC, Evangelista, Brown NP, Pillar CM, Sahm DF, Thornsberry C. Differences in carbapemen in vitro activity among lower respiratory tract an ICU isolates of P. aeruginosa: 2006-2008 TRUST data. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, September 12-15, 2009. Abstract: C2-629.
18. Gales AC, Cereda RF, Azevedo HD. Antimicrobial activity of doripenem against gramnegative pathogens: Results from INVITAADORI Brazilian Study. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, September 12-15, 2009. Abstract: E-177.
19. Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized ß-lactamases. Antimicrob Agents Chemother 2004; 48: 1313-9.
20. Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004; 48: 3136-40.
21. Livermore DM. Of Pseudomonas aeruginosa, porins pumps and carbapenems. J Antimicrob Agents Chemother 2001; 47: 247-50.
22. Llanes C, Hocquet D, Vogne C, Benali-Baitich D, Neuwirth C, Plesiat P. Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously. Antimicrob Agents Chemother 2004; 48:1797-802.
23. Quale J, Bratu S, Gupta J, Landman D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2006; 50: 1633-41.
24. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potencial. Antimicrob Agents Chemother 2004; 48: 3086-92.
25. Asensio A, Cantón R, Vaque J, Calbo-Torrecillas F, Herruzo R, Arribas JL, et al. Prevalence of infection by carbapenem-resistant Acinetobacter baumannii in Spain (1999-2005). Enferm Infecc Microbiol Clin 2008; 26: 199-204.
26. Marti S, Sanchez-Céspedes J, Alba V, Vila J. In vitro activity of doripenem against Acinetobacter baumannii clinical isolates. Int J Antimicrob Agents 2009; 33: 181-2.
27. Fernández-Cuenca F, Pascual A, Ribera A, Vila J, Bou G, Cisneros JM, et al. Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000). Enferm Infecc Microbiol Clin 2004; 22: 267-71.
28. Ribera A, Vila J, Fernández-Cuenca F, Martinez-Martinez L, Pascual A, Beceiro A. Type 1 integrons in epidemiologically unrelated Acinetobacter baumannii isolates collected at Spanish hospitals. Antimicrob Agents Chemother 2004; 48: 364-5.
29. Oteo J, García-Estébanez C, Migueláñez S, Campos J, Martí S, Vila J, et al. Red Española de Investigación en Patología Infecciosa. Genotypic diversity of imipenem resistant isolates of Acinetobacter baumannii in Spain. J Infect 2007; 55: 260-6.
30. Floren L, Wikler M, Kilfoil T, Ge Y. A phase I, double-blind, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics (PK) of prolonged-infusion regimens of dori penem(DOR) in healthy subjects. 44th Intersci Conf Antimicrob Agents Chemother; October 20 - November 2, 2004; Washington, DC. Abstract A-16.
31. Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005; 49: 3944-7.
32. Cirillo I, Vaccaro N, Turner K, Solanki B, Natarajan J, Redman R. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. J Clin Pharmacol 2009; 49: 798-806.
33. Kim A, Baneviciu MA, Nicolau DP. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother 2008; 52: 2497-502.